Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 126

1.

Association Between Newborn Metabolic Profiles and Pediatric Kidney Disease.

Sood MM, Murphy MSQ, Hawken S, Wong CA, Potter BK, Burns KD, Tsampalieros A, Atkinson KM, Chakraborty P, Wilson K.

Kidney Int Rep. 2018 Feb 10;3(3):691-700. doi: 10.1016/j.ekir.2018.02.001. eCollection 2018 May.

2.

Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease (Can-SOLVE CKD): Form and Function.

Levin A, Adams E, Barrett BJ, Beanlands H, Burns KD, Chiu HH, Chong K, Dart A, Ferera J, Fernandez N, Fowler E, Garg AX, Gilbert R, Harris H, Harvey R, Hemmelgarn B, James M, Johnson J, Kappel J, Komenda P, McCormick M, McIntyre C, Mahmud F, Pei Y, Pollock G, Reich H, Rosenblum ND, Scholey J, Sochett E, Tang M, Tangri N, Tonelli M, Turner C, Walsh M, Woods C, Manns B.

Can J Kidney Health Dis. 2018 Jan 17;5:2054358117749530. doi: 10.1177/2054358117749530. eCollection 2018.

3.

PGE2 EP1 receptor inhibits vasopressin-dependent water reabsorption and sodium transport in mouse collecting duct.

Nasrallah R, Zimpelmann J, Eckert D, Ghossein J, Geddes S, Beique JC, Thibodeau JF, Kennedy CRJ, Burns KD, Hébert RL.

Lab Invest. 2018 Mar;98(3):360-370. doi: 10.1038/labinvest.2017.133. Epub 2017 Dec 18.

PMID:
29251736
4.

High glucose increases the formation and pro-oxidative activity of endothelial microparticles.

Burger D, Turner M, Xiao F, Munkonda MN, Akbari S, Burns KD.

Diabetologia. 2017 Sep;60(9):1791-1800. doi: 10.1007/s00125-017-4331-2. Epub 2017 Jun 10.

PMID:
28601907
5.

Treatment with enalapril and not diltiazem ameliorated progression of chronic kidney disease in rats, and normalized renal AT1 receptor expression as measured with PET imaging.

Ismail B, deKemp RA, Croteau E, Hadizad T, Burns KD, Beanlands RS, DaSilva JN.

PLoS One. 2017 May 19;12(5):e0177451. doi: 10.1371/journal.pone.0177451. eCollection 2017.

6.

Hypertension Canada's 2017 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults.

Leung AA, Daskalopoulou SS, Dasgupta K, McBrien K, Butalia S, Zarnke KB, Nerenberg K, Harris KC, Nakhla M, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tran KC, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GVR, Gryn SE, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Sivapalan P, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NRC, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Kline G, Leiter LA, Jones C, Côté AM, Woo V, Kaczorowski J, Trudeau L, Tsuyuki RT, Hiremath S, Drouin D, Lavoie KL, Hamet P, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; Hypertension Canada.

Can J Cardiol. 2017 May;33(5):557-576. doi: 10.1016/j.cjca.2017.03.005. Epub 2017 Mar 10. Erratum in: Can J Cardiol. 2017 Dec;33(12 ):1733-1734.

PMID:
28449828
7.

Precision Medicine for Hypertension Management in Chronic Kidney Disease: Relevance of SPRINT for Therapeutic Targets in Nondiabetic Renal Disease.

Ruzicka M, Burns KD, Hiremath S.

Can J Cardiol. 2017 May;33(5):611-618. doi: 10.1016/j.cjca.2017.01.007. Epub 2017 Jan 20. Review.

PMID:
28365055
8.

The KRESCENT Program (2005-2015): An Evaluation of the State of Kidney Research Training in Canada.

Burns KD, Levin A, Fowler E, Butcher L, Turcotte M, Makarchuk MJ, Macaluso B, Larivière V, Sherman PM.

Can J Kidney Health Dis. 2017 Feb 16;4:2054358117693354. doi: 10.1177/2054358117693354. eCollection 2017.

9.

Measurement of Angiotensin Converting Enzyme 2 Activity in Biological Fluid (ACE2).

Xiao F, Burns KD.

Methods Mol Biol. 2017;1527:101-115. doi: 10.1007/978-1-4939-6625-7_8.

PMID:
28116710
10.

Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis.

Callera GE, Antunes TT, Correa JW, Moorman D, Gutsol A, He Y, Cat AN, Briones AM, Montezano AC, Burns KD, Touyz RM.

Biosci Rep. 2016 Oct 27;36(5). pii: e00398. Print 2016 Oct.

11.

The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes.

Burns KD, Lytvyn Y, Mahmud FH, Daneman D, Deda L, Dunger DB, Deanfield J, Dalton RN, Elia Y, Har R, Van JA, Bradley TJ, Slorach C, Hui W, Xiao F, Zimpelmann J, Mertens L, Moineddin R, Reich HN, Sochett E, Scholey JW, Cherney DZ.

Am J Physiol Renal Physiol. 2017 Feb 1;312(2):F335-F342. doi: 10.1152/ajprenal.00438.2016. Epub 2016 Oct 12.

12.

Transfer of microRNA-486-5p from human endothelial colony forming cell-derived exosomes reduces ischemic kidney injury.

Viñas JL, Burger D, Zimpelmann J, Haneef R, Knoll W, Campbell P, Gutsol A, Carter A, Allan DS, Burns KD.

Kidney Int. 2016 Dec;90(6):1238-1250. doi: 10.1016/j.kint.2016.07.015. Epub 2016 Sep 17.

13.

The association of urinary sodium excretion and the need for renal replacement therapy in advanced chronic kidney disease: a cohort study.

Mazarova A, Molnar AO, Akbari A, Sood MM, Hiremath S, Burns KD, Ramsay TO, Mallick R, Knoll GA, Ruzicka M.

BMC Nephrol. 2016 Sep 5;17(1):123. doi: 10.1186/s12882-016-0338-z.

14.

The impact of intervention strategies that target arterial stiffness in end-stage renal disease: a systematic review protocol.

Rodriguez RA, Shea B, Hae R, Burns KD.

Syst Rev. 2016 Jul 19;5(1):118. doi: 10.1186/s13643-016-0286-5. Review.

15.

Protein Kinase C-δ Mediates Shedding of Angiotensin-Converting Enzyme 2 from Proximal Tubular Cells.

Xiao F, Zimpelmann J, Burger D, Kennedy C, Hébert RL, Burns KD.

Front Pharmacol. 2016 Jun 1;7:146. doi: 10.3389/fphar.2016.00146. eCollection 2016.

16.

Hypertension Canada's 2016 Canadian Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention, and Treatment of Hypertension.

Leung AA, Nerenberg K, Daskalopoulou SS, McBrien K, Zarnke KB, Dasgupta K, Cloutier L, Gelfer M, Lamarre-Cliche M, Milot A, Bolli P, Tremblay G, McLean D, Tobe SW, Ruzicka M, Burns KD, Vallée M, Prasad GV, Lebel M, Feldman RD, Selby P, Pipe A, Schiffrin EL, McFarlane PA, Oh P, Hegele RA, Khara M, Wilson TW, Penner SB, Burgess E, Herman RJ, Bacon SL, Rabkin SW, Gilbert RE, Campbell TS, Grover S, Honos G, Lindsay P, Hill MD, Coutts SB, Gubitz G, Campbell NR, Moe GW, Howlett JG, Boulanger JM, Prebtani A, Larochelle P, Leiter LA, Jones C, Ogilvie RI, Woo V, Kaczorowski J, Trudeau L, Petrella RJ, Hiremath S, Drouin D, Lavoie KL, Hamet P, Fodor G, Grégoire JC, Lewanczuk R, Dresser GK, Sharma M, Reid D, Lear SA, Moullec G, Gupta M, Magee LA, Logan AG, Harris KC, Dionne J, Fournier A, Benoit G, Feber J, Poirier L, Padwal RS, Rabi DM; CHEP Guidelines Task Force.

Can J Cardiol. 2016 May;32(5):569-88. doi: 10.1016/j.cjca.2016.02.066. Epub 2016 Mar 10.

PMID:
27118291
17.

Reproducibility of carotid-femoral pulse wave velocity in end-stage renal disease patients: methodological considerations.

Rodriguez RA, Cronin V, Ramsay T, Zimmerman D, Ruzicka M, Burns KD.

Can J Kidney Health Dis. 2016 Apr 1;3:20. doi: 10.1186/s40697-016-0109-6. eCollection 2016.

18.

PGE2 receptor EP3 inhibits water reabsorption and contributes to polyuria and kidney injury in a streptozotocin-induced mouse model of diabetes.

Hassouneh R, Nasrallah R, Zimpelmann J, Gutsol A, Eckert D, Ghossein J, Burns KD, Hébert RL.

Diabetologia. 2016 Jun;59(6):1318-28. doi: 10.1007/s00125-016-3916-5. Epub 2016 Mar 19.

PMID:
26995650
19.

Pincer nails following arteriovenous fistula creation.

Clark EG, Burns KD.

Kidney Int. 2015 Oct;88(4):918. doi: 10.1038/ki.2015.12. No abstract available.

PMID:
26422629
20.

Re: Microparticles: markers and mediators of sepsis-induced microvascular dysfunction, immunosuppression, and AKI.

Burger D, Erdbrügger U, Burns KD.

Kidney Int. 2015 Oct;88(4):915. doi: 10.1038/ki.2015.208. No abstract available.

PMID:
26422626

Supplemental Content

Loading ...
Support Center